Auriga acquires Athlon's 'common cold' Levall product line

By Elaine Rigoli

Tampa, Fla., Sept. 11 - Auriga Laboratories, Inc. has acquired a license to market the Levall family of common-cold remedy prescription drug products from Athlon Pharmaceuticals in a transaction worth up to $20 million.

Levall generated $9.7 million of sales in 2005 and $9.6 million of sales in 2004 while owned by Athlon, according to a news release.

The Levall product line includes four trademarked lines that address medical needs in the multibillion-dollar market for respiratory and common cold ailments.

Under the agreement, the Norcross, Ga.-based specialty pharmaceutical company will use at least 50 sales representatives to promote the product line by the end of the first year.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.